Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeuroVita dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- NeuroVita Clinic
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The NeuroVita dendritic cell vaccine is a personalized autologous immunotherapy developed by the NeuroVita Clinic for the treatment of brain metastases from breast cancer (BMBC). The vaccine is produced by isolating dendritic cells from the patient's peripheral blood and loading them with tumor-specific antigens derived from the patient's own tumor samples or recombinant proteins identified through proteome mapping and transcriptome profiling. This therapy is typically administered as part of a multi-component regimen that includes allogeneic or autologous hematopoietic stem cells and cytotoxic lymphocytes. The vaccine's mechanism of action involves the activation of the patient's immune system to recognize and target tumor cells and tumor stem cells, aiming to convert acute, lethal neurooncological processes into manageable chronic conditions and improve overall survival and quality of life.
- Other names
- Dendritic vaccineDV
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on NeuroVita dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroVita dendritic cell vaccine.